D

Dana-Farber Cancer Institute | Pediatric Hematologic Malignancy

Research site
(Unclaimed)
Location
450 Brookline Avenue, Boston, Massachusetts, United States of America
Site insights

Top conditions

Leukemia (86 trials)

Breast Cancer (82 trials)

Cancer (67 trials)

Prostatic Cancer (56 trials)

Lymphoma (55 trials)

Top treatments

Cisplatin
Bevacizumab
Carboplatin
Paclitaxel
Dexamethasone
Bortezomib
Cyclophosphamide
Gemcitabine
Docetaxel
Temozolomide

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

73 of 808
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll...

Enrolling
Metastatic Cancer
Advanced Gastrointestinal Stromal Tumors
Drug: CGT9486
Drug: Sunitinib

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-c...

Enrolling
Multiple Myeloma
Drug: Cilta-cel

This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with place...

Active, not recruiting
Breast Cancer
Drug: Placebo
Drug: Palbociclib

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combin...

Active, not recruiting
Advanced Solid Tumors Cancer
Drug: Osimertinib
Drug: Nivolumab

This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants...

Active, not recruiting
Myelofibrosis (MF)
Drug: Navitoclax
Drug: Ruxolitinib

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants...

Active, not recruiting
Myelodysplastic Syndromes (MDS)
Drug: Venetoclax
Drug: Azacitidine

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting
Cytochrome P-450
Antineoplastic Agents, Hormonal
Drug: Placebo for Abemaciclib
Drug: Abemaciclib

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectom...

Active, not recruiting
Prostatic Neoplasms
Drug: Placebo
Drug: Apalutamide

This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD1...

Active, not recruiting
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Biological: AUTO1

This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and e...

Active, not recruiting
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Elotuzumab

This is a phase I/II, open-label, multicenter study . During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunog...

Not yet enrolling
Solid Tumor, Adult
Drug: HB0045 Drug Product

This research study is evaluating a combination of drugs called Ofatumumab and Idelalisib as a possible treatment for Chronic Lymphocytic Leukemia (C...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Ofatumumab
Drug: Idelalisib

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2Ds) of JNJ-75276617 in combination with a conventional chemotherapy bac...

Begins enrollment in 1 month
Acute Leukemia of Ambiguous Lineage
Acute Leukemias
Drug: Dexamethasone
Drug: Pegaspargase

This research study is studying a chemotherapy drug Lenalidomide as a possible treatment for one of three histiocyte disorders: Langerhans cell histi...

Active, not recruiting
Histiocytic Sarcoma (HS)
Langerhans Cell Histiocytosis (LCH)
Drug: Lenalidomide

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or me...

Enrolling
Locally Advanced Solid Tumors
Primary CNS Tumors
Drug: Oral repotrectinib (TPX-0005)

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in particip...

Enrolling
Carcinoma, Non-Small-Cell Lung
Drug: Placebo
Drug: Selpercatinib

The purpose of this study is to determine the safety and tolerability of SNDX-5613 when given in combination with 2 different chemotherapy regimens i...

Active, not recruiting
Acute Lymphocytic Leukemia
Mixed Phenotype Acute Leukemia
Drug: Chemotherapy Regimen 2
Drug: Chemotherapy Regimen 1

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free sur...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Daratumumab SC: daratumumab + rHuPH20

Trial sponsors

Dana-Farber Cancer Institute logo

Dana-Farber Cancer Institute (252 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems